Ipsen (IPN) H1 2024 earnings summary

Executive summary

• Total sales for H1 2024 grew 9.5% at constant exchange rates to €1,659.3 million, driven by Oncology and Neuroscience portfolios, with upgraded full-year guidance.

• Core operating margin reached 32.4%, with free cash flow of €394 million and IFRS consolidated net profit up 19.1% to €232.3 million.

• Achieved key U.S. launches for Onivyde (first-line pancreatic cancer) and Iqirvo (second-line PBC), with further CHMP opinions expected for Iqirvo and Bylvay.

• Pipeline advanced with in-licensing of tovorafenib (ex-US) for pediatric oncology and expansion of collaborations for Cabometyx.

• Upgraded FY 2024 guidance for total sales growth and core operating margin.

Financial highlights

• Total sales reached €1,659.3 million, up 9.5% at constant exchange rates; core operating income rose 2.8% to €538 million.

• IFRS consolidated net profit increased 19.1% to €232.3 million; EBITDA up 2.6% to €582.7 million.

• Free cash flow reached €393.5 million, up 5.9% year-over-year; closing net debt at €6.8 million.

• Gross margin declined by 1.6 points due to sales mix and higher royalties; R&D costs rose to 19.5% of sales.

• SG&A costs grew 4%, with improved efficiency post-acquisitions; SG&A ratio to sales improved by 1.4 points to 34.6%.

Outlook and guidance

• Upgraded 2024 guidance: total sales growth expected above 7% at constant exchange rates (previously above 6%).

• Core operating margin anticipated above 30% of sales, with lower profitability in H2 due to increased investment and seasonality.

• Guidance assumes accelerated Somatuline erosion from generics, offset by higher contributions from new launches.

• Currency headwinds expected to impact total sales by around 1% for the full year.